Welcome to our dedicated page for Voyager Therapeutics news (Ticker: VYGR), a resource for investors and traders seeking the latest updates and insights on Voyager Therapeutics stock.
Voyager Therapeutics, Inc., listed on Nasdaq under the symbol VYGR, is a pioneering gene therapy company dedicated to developing transformative treatments for severe neurological diseases. Founded in 2014 by leaders in the fields of AAV gene therapy and neuroscience, Voyager focuses on conditions like Parkinson's disease, a monogenic form of amyotrophic lateral sclerosis (ALS), and Friedreich's ataxia. Headquartered in Cambridge, Massachusetts, the company leverages its proprietary TRACER™ AAV capsid discovery platform to create gene therapies with high efficacy and broad brain penetration.
The company’s gene therapy platform, TRACER™ (Tropism Redirection of AAV by Cell-type-specific Expression of RNA), allows for the engineering, optimization, and delivery of AAV-based therapies. This platform has enabled the discovery of novel capsids that exhibit enhanced penetration of the blood-brain barrier and targeted delivery to central nervous system (CNS) tissues.
Voyager's pipeline includes several promising programs. The most advanced is the anti-tau antibody VY-TAU01, aimed at treating Alzheimer’s disease and expected to generate key tau PET imaging data by 2026. Other pipeline projects include gene therapies targeting SOD1 for ALS, and FXN gene therapy for Friedreich’s ataxia.
Financially, Voyager maintains a robust balance sheet. As of December 31, 2023, Voyager reported approximately $431 million in pro-forma cash. This financial strength supports the company’s ongoing clinical trials and the advancement of its gene therapy programs. Voyager collaborates with several industry leaders, including Alexion, AstraZeneca Rare Disease, Novartis Pharma AG, Neurocrine Biosciences, Inc., and Sangamo Therapeutics, Inc. These partnerships provide additional resources and expertise to accelerate the development and commercialization of its therapeutic candidates.
Voyager's achievements have garnered attention within the biotechnology industry. The company's commitment to innovation and the development of life-changing treatments makes it a significant player in the field of gene therapy.
For the latest updates, financial results, and news about Voyager Therapeutics, visit their website at www.voyagertherapeutics.com.
FAQ
What is the current stock price of Voyager Therapeutics (VYGR)?
What is the market cap of Voyager Therapeutics (VYGR)?
What is Voyager Therapeutics’ primary focus?
What is the TRACER™ platform?
Where is Voyager Therapeutics headquartered?
What are some key programs in Voyager’s pipeline?
Who are some of Voyager’s strategic partners?
What is the financial condition of Voyager Therapeutics?
When was Voyager Therapeutics founded?
What is the significance of VY-TAU01?
How does Voyager’s TRACER platform contribute to their therapies?
Where can I find more information about Voyager Therapeutics?
